HUTCHMED (CHINA) LIMIT

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

24 3 2021 08:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

24 3 2021 02:00:00 提供 Nasdaq GlobeNewswire

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

04 3 2021 06:00:02 提供 Nasdaq GlobeNewswire

Chi-Med to Announce 2020 Final Results

03 2 2021 01:00:00 提供 Nasdaq GlobeNewswire

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

14 1 2021 04:00:00 提供 Nasdaq GlobeNewswire

Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases

10 1 2021 19:00:00 提供 Nasdaq GlobeNewswire